Cytogenetically Unrelated Clones in Hematologic Malignancies.
- Author:
Sungeun CHO
1
;
Jungwon HUH
;
Chumyung SEONG
;
Whasoon CHUNG
Author Information
1. Department of Laboratory Medicine, Ewha Womans University, College of Medicine, Seoul, Korea. JungWonH@hitel.net
- Publication Type:Original Article
- Keywords:
Unrelated clones;
Chromosome;
Hematologic malignancies
- MeSH:
Bone Marrow;
Clone Cells*;
Diagnosis;
Female;
Hematologic Neoplasms*;
Humans;
Leukemia, Biphenotypic, Acute;
Lymphoma, Non-Hodgkin;
Mesylates;
Multiple Myeloma;
Myeloproliferative Disorders;
Philadelphia Chromosome;
Prevalence;
Trisomy;
Imatinib Mesylate
- From:The Korean Journal of Laboratory Medicine
2004;24(3):189-193
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The origin of hematologic malignancies has been known to be monoclonal. In most cases, the same or obviously related chromosomal abnormliaties are found and cytogenetically unrelated clones are uncommon. We evaluated the prevalence and clinical significance of patients with cytogenetically unrelated clones in hematologic malignancies. METHODS: Included in the study were 324 patients who had been diagnosed with the following hematologic malignancies at Ewha Womans University, Mokdong Hospital: AML (93 cases), MDS (27), CML (51), myeloproliferative disorder (38), acute biphenotypic leukemia (8), ALL (44), CLL (9), multiple myeloma (MM, 40), and Non-Hodgkin's lymphoma with bone marrow involvement (14). RESULTS: The overall prevalence of hematologic malignancies with cytogenetically unrelated clones at diagnosis was 0.9% (3/324). Of AML patients, 1.1% (1/93) had unrelated clones, CLL 11.1% (1/9), and MM 2.5% (1/40). The other hematologic malignancies did not show cytogenetically unrelated clones. The AML patient had add(11)(q23)/add(1)(p36.3); the CLL patient had +12/ del(13)(q22); and the MM patient had +der(1)t(1;13)(p12;q12), -13/-X, +5, +7, -8, -12, -13, add(14) (q32), +15, -16, +19, -20, -22, -22. We also detected an unrelated clone of trisomy 8 in Philadelphia chromosome negative cells from a CML patient who was treated with imatinib mesylate. CONCLUSIONS: Hematologic malignancies with cytogenetically unrelated clones are uncommon. This report highlights the importance of the conventional chromosomal analysis in that an unrelated clone in philadelphia chromosome negative cells may be detected in a CML case.
